Bacil Pharma Ltd. | Income Statement
Fiscal year is April-March. All values INR Thousands.
2014
2015
2016
2017
2018
2019
Cost of Goods Sold (COGS) incl. D&A
385.70
445.50
7.80
32.30
-
91
Gross Income
385.70
445.50
7.80
32.30
-
91
SG&A Expense
578.40
673.40
1,287.40
1,685.90
3,205.00
4,284
EBIT
964.10
1,124.90
1,295.30
1,718.20
3,307.00
4,375
Unusual Expense
-
-
-
-
36,948.00
-
Non Operating Income/Expense
454.40
624.60
443.00
1,518.40
2,741.00
941
Interest Expense
0.60
0.30
0.70
0.80
-
-
Pretax Income
1,090.90
318.10
670.60
20.60
37,514.00
3,436
Income Tax
-
-
-
-
14.00
11
Consolidated Net Income
1,090.90
318.10
670.60
20.60
37,500.00
3,423
Net Income
1,090.90
318.10
670.60
20.60
37,500.00
3,423
Net Income After Extraordinaries
1,090.90
318.10
670.60
20.60
37,500.00
3,423
Net Income Available to Common
1,090.90
318.10
670.60
20.60
37,500.00
3,423
EPS (Basic)
0.19
0.05
0.11
0.00
6.37
0.58
Basic Shares Outstanding
5,890.00
5,890.00
5,890.00
5,890.00
-
-
EPS (Diluted)
0.19
0.05
0.11
0.00
-
-
Diluted Shares Outstanding
5,890.00
5,890.00
5,890.00
5,890.00
-
-
EBITDA
907.90
1,086.40
1,287.40
1,685.90
3,205.00
4,284
Other Operating Expense
-
6.00
-
-
-
-
Non-Operating Interest Income
328.30
182.40
182.50
180.00
-
-
About Bacil Pharma
View Profile
